First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report Article

Hall, Matthew D, Odia, Yazmin, Allen, Joshua E et al. (2019). First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report . JOURNAL OF NEUROSURGERY-PEDIATRICS, 23(6), 719-725. 10.3171/2019.2.PEDS18480

cited authors

  • Hall, Matthew D; Odia, Yazmin; Allen, Joshua E; Tarapore, Rohinton; Khatib, Ziad; Niazi, Toba N; Daghistani, Doured; Schalop, Lee; Chi, Andrew S; Oster, Wolfgang; Mehta, Minesh P

sustainable development goals

publication date

  • June 1, 2019

published in

keywords

  • Clinical Neurology
  • DRD2
  • H3 K27M
  • HISTONE H3.3
  • INHIBITION
  • INTEGRATED STRESS-RESPONSE
  • Life Sciences & Biomedicine
  • MUTATION
  • Neurosciences & Neurology
  • ONC201
  • Pediatrics
  • SUBGROUPS
  • Science & Technology
  • Surgery
  • TARGET
  • TRIAL
  • TUMORS
  • diffuse intrinsic pontine glioma
  • diffuse midline glioma
  • oncology
  • targeted therapy

Digital Object Identifier (DOI)

publisher

  • AMER ASSOC NEUROLOGICAL SURGEONS

start page

  • 719

end page

  • 725

volume

  • 23

issue

  • 6